PRLD - Prelude Therapeutics Incorporated Earnings growth forecast for next year

Symbol and logo of brand Prelude Therapeutics (PRLD)

Prelude Therapeutics (PRLD) relies on a scalable inhibitor discovery platform for oncology. This chart in the GURU.Markets terminal illustrates the valuation of future earnings per share growth, where -18.70 captures the magnitude of this parameter. This price action confirms a dependency on early-stage small molecule test results, while the absence of commercial products renders cash flows unpredictable.

Prelude (PRLD): Expected net earnings per share growth next year from 07/04/2022 to 11/15/2026

Metric breakdowns and analytics for Prelude Therapeutics Inc. (PRLD)

- price and consensus price forecast:
Price Chart Prelude|PRLD - Forecast Levels Chart
- market capitalization statistics:
Market Capitalization Prelude|PRLD - Value Adjusted for Debt and Cash
- book capitalization indicators:
Net Assets per Single Share Prelude Therapeutics|PRLD - Total Stockholders' Equity|Market Value to Book Value Ratio preludetx.com|PRLD - Total Business Assets
- company total debt and liquidity indicators:
Debt to Equity Prelude Therapeutics|PRLD - Long-Term Liabilities to Capital|Short-Term Debt to Capital Prelude Therapeutics Incorporated|PRLD - Company Aggregate Debt|Debts to Book Capitalization Prelude Therapeutics|PRLD - Long-Term Debt|Company Short-Term Debt Prelude Therapeutics|Quick Liquidity preludetx.com
- net income and valuation ratios data:
PRLD - Profit After Tax|Expected Profit Prelude Therapeutics|PRLD - Company Value to Net Income|Forward P/E Multiple Prelude Therapeutics Inc.|PRLD - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prelude Therapeutics Inc.|PRLD - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Prelude Therapeutics|PRLD - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth preludetx.com|PRLD - Earnings per share growth this year|Earnings growth forecast for next year Prelude Therapeutics
- total revenue and sales volume data:
PRLD - Company Total Revenue|Company Future Sales Volume preludetx.com|PRLD - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Prelude Therapeutics
General company analysis:Prelude Therapeutics, PRLD
Core merchandise of Prelude Therapeutics Incorporated

This indicator reflects market consensus expectations regarding the rate of change in earnings per share for the upcoming period. By analyzing the modeled EPS growth for the next fiscal year, investors track the dynamics of analyst estimate revisions, where curve volatility signals a shift in fundamental sentiment. For Prelude Therapeutics (PRLD), this forecast depends directly on the effectiveness of AI model implementation and the robotization of screening in the development of anti-tumor drugs.

Competitors of Prelude Therapeutics

Net earnings per share growth forecast for next year Corvus Pharmaceuticals Inc|Elicio Therapeutics - Net earnings per share change forecast for next year